Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
313 GBX | +0.97% | +5.21% | +10.60% |
26/04 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
26/04 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.60% | 3.33B | |
+31.52% | 690B | |
+24.54% | 546B | |
-5.21% | 358B | |
+17.02% | 323B | |
+5.01% | 287B | |
+13.49% | 235B | |
+4.25% | 199B | |
-10.43% | 195B | |
+3.98% | 161B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- HUTCHMED China : , Junshi Bio Start Phase III Trial of Combination Therapy for Neuroendocrine Carcinoma in China